BSX

#121
Boston Scientific Corp.
76.68
+2.80%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
76.31
76.68
Intervallo Annuale
72.69
109.49
Variazione giornaliera
+2.80%
Variazione Mensile
-17.88%
Variazione di 6 mesi
-27.56%
Variazione Annuale
-24.27%
Chiusura Precedente
74.59
Open
76.31
Bid
Ask
Low
76.31
High
76.68
Volume
5 199
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
  • Market Capitalization 113.52 B
  • Employee 59 K
  • Founded 1979
  • CEO Michael F. Mahoney
  • Website www.bostonscientific.com
  • Headquarter Delaware, United States
  • FIGI BBG000C0LW92
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
49.15
Price to sales ratio
7.1
Dividends per share
—
Dividend yield %
—

Boston Scientific Corporation

Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator. Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

Notizie